31 TWENTYFOURSEVENBIOPHARMA Issue 3 / October 2025 of specialized therapeutic business units in CNS, Dermatology, Ophthalmology and Oncology. His expertise in structuring operations around specific therapeutic areas aligns closely with Julius Clinical’s ambitious growth strategy in CNS, Cardiometabolic and rare diseases. “I am excited to join Julius Clinical. With its strong scientific heritage and operational agility, the company has earned a reputation for delivering high-quality, flexible clinical trials for both biotech and pharma across Europe and North America. As treatments become increasingly personalized, the industry is in greater need of mid-sized, therapeutically focused global CROs. Julius Clinical’s operating model, combining deep scientific expertise, effective site networks, strong customer partnerships, and global reach, positions us well to lead in this space. Supported by our talented team, I see tremendous opportunity to expand our global presence, deepen therapeutic expertise, and leverage advanced technologies to help our customers bring better treatments to patients worldwide,” said Bassem Saleh. Daniel Spasic, Chairman of the Board, Julius Clinical, commented, “I’ve had the privilege of working closely with Bassem over the years. His extensive experience leading and scaling global clinical CROs, combined with his deep understanding of industry dynamics and the needs of our biotech and pharma partners, positions him to contribute meaningfully to Julius Clinical’s long-term growth. In addition, his medical background aligns perfectly with our deep scientific roots, further strengthening our commitment to advancing clinical research worldwide with our clients.” Veranova, a global leader in the development and manufacturing of specialty and complex active pharmaceutical ingredients (API) for the pharmaceutical and biotech sectors, is pleased to announce the appointment of Joe Torres-Ocasio as Senior Vice President and Chief Operating Officer (COO). Joe will lead Veranova’s global operations across its manufacturing network in Europe and North America, and will also oversee the company’s Engineering, Environmental Health & Safety (EHS) and Supply Chain/ Operational Excellence functions. Prior to joining Veranova, he served as Vice President of Global Operations for Catalent’s Biologics division, playing a pivotal role in transforming the performance of several key operations. His career also includes leadership roles at Baxter Healthcare International, where he led the turnaround and growth of critical sites before becoming a regional Vice President. Joe began his career at Amgen as a manufacturing leader where he led a high-impact Lean transformation. He later held senior operational roles at Immucor and Therapeutic Proteins International. He holds a dual BS degree in Chemical Engineering and Industrial Biotechnology from Universidad de Puerto Rico, as well as an MBA from Universidad Interamericana de Puerto Rico. “Joe’s deep operational expertise and proven leadership track record make him an exceptional addition to our Leadership Team” said Mike Riley, Chief Executive Officer of Veranova. “His ability to drive transformational change at scale across multiple technologies will be instrumental in driving operational excellence and delivering value to our customers and patients.” This appointment comes at a pivotal time for Veranova, following a $50 million investment into its Devens, MA facility aimed at strengthening US-based infrastructure for the production of highly potent compounds, antibody-drug conjugates (ADCs), and novel bioconjugates. Veranova appoints Joe Torres-Ocasio as Senior Vice President, Chief Operating Officer NEWS
RkJQdWJsaXNoZXIy MjY2OTA4MA==